Drug Development Pipeline
Restore CFTR Protein
Riociguat is a novel therapy that stimulates sGC, an enzyme in the cardiopulmonary system and the receptor for nitric oxide (NO). Preclinical data has shown evidence that riociguat can result in improved function of the CFTR protein as a chloride channel, moving salt and fluids in and out of cells.
A Phase 2 trial for adults who have two copies of the F508del mutation was terminated in 2017. No safety concerns were identified.
No further clinical development in CF is planned at this time.
This program is sponsored by Bayer and is being conducted within the Therapeutics Development Network.
Recent Riociguat Studies
Completed with Results
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More